Abstract OC-009
| Median age (range) | 37 (26–62) |
| M/F ratio | 2:11 |
| CD/UC | 8:5 |
| Number of patients on concurrent immunosuppression | 7 |
| Median (range) duration of infliximab in months prior to DILE | 14 (1–52) |
| Median (range) number of infliximab infusions prior to DILE | 10 (2–30) |
| Recurrence of lupus like reaction after exposure to second anti-TNF agent | 25% |
| Median (range) period of treatment with second anti-TNF agent | 5 months (2–6) |